Bulk Pharmaceutical API Sources for gadopiclenol

Bulk Pharmaceutical API Sources for gadopiclenol

Vendor	Vendor Homepage	Vendor Sku	API Url
BenchChem		B1258881
THE BioTek		bt-1591210
Starshine Chemical		2023-05-5H05000

GADOPICLENOL Bulk API Sourcing Analysis

Last updated: February 19, 2026

This report analyzes the current landscape of bulk active pharmaceutical ingredient (API) sources for gadopiclenol, a gadolinium-based contrast agent. The analysis focuses on API manufacturers, their production capacities, regulatory compliance, and potential supply chain risks.

What is Gadopiclenol and its Market Position?

Gadopiclenol is a macrocyclic gadolinium-based contrast agent for magnetic resonance imaging (MRI). It offers a favorable relaxivity profile, allowing for lower doses compared to some existing agents. Approved by the U.S. Food and Drug Administration (FDA) in 2023 under the brand name VUEWAY, it is positioned to compete with established MRI contrast agents like gadobutrol (Gadovist) and gadoterate meglumine (Dotarem). The global MRI contrast agent market is projected to reach approximately USD 4.5 billion by 2027, with gadopiclenol targeting a significant segment of this market [1].

Who are the Primary Bulk API Manufacturers for Gadopiclenol?

Manufacturing of gadopiclenol API requires specialized expertise in chelation chemistry and stringent quality control due to the use of gadolinium. Currently, the primary bulk API manufacturers identified are:

• Bracco Imaging S.p.A. Bracco is the originator and developer of gadopiclenol. They possess in-house API manufacturing capabilities. Their facility in Milan, Italy, is a key production site.
• GE HealthCare. While primarily a marketer of the finished product (Luciem), GE HealthCare has established partnerships and likely has access to a dedicated API supply chain, potentially involving contract manufacturing organizations (CMOs).
• Contract Manufacturing Organizations (CMOs). Several highly specialized CMOs with experience in complex API synthesis, particularly those with Good Manufacturing Practice (GMP) compliance for radiopharmaceuticals and contrast agents, are likely involved in the supply chain, either directly for Bracco or indirectly for other distributors. Identifying specific CMOs is challenging due to proprietary agreements.

What are the Key Manufacturing Considerations for Gadopiclenol API?

The synthesis of gadopiclenol API involves multiple complex steps, demanding precision and adherence to strict quality standards. Key considerations include:

• Gadolinium Sourcing: Gadolinium is a rare-earth element, and its consistent supply can be a factor. The purity and form of the gadolinium salt used as a precursor are critical.
• Chelation Process: The core of gadopiclenol synthesis is the macrocyclic chelation of gadolinium. This process requires precise control of reaction conditions to ensure the formation of a stable, non-toxic complex.
• Impurities Control: Controlling free gadolinium ions and other process-related impurities is paramount for patient safety. Regulatory agencies have strict limits on such impurities.
• Scale-Up Capabilities: Meeting global demand requires API manufacturers to have robust scale-up capabilities from pilot to commercial production volumes.
• Regulatory Compliance: Manufacturing facilities must comply with current Good Manufacturing Practices (cGMP) as mandated by regulatory bodies such as the FDA, European Medicines Agency (EMA), and others. This includes rigorous validation of manufacturing processes, analytical methods, and quality control systems.

What are the Regulatory Requirements for Gadopiclenol API?

Regulatory approval for gadopiclenol API is contingent upon meeting comprehensive quality and safety standards. Key regulatory aspects include:

• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies (e.g., FDA DMF, CEP for Europe). These confidential documents detail the manufacturing process, quality controls, and facility information. Bracco Imaging would have submitted a DMF for gadopiclenol.
• cGMP Compliance: Facilities producing the API must be inspected and deemed compliant with cGMP guidelines. This involves adherence to detailed documentation, process validation, and quality assurance protocols. Inspections are conducted regularly by regulatory authorities.
• Impurity Profiling: Rigorous analytical testing to identify and quantify all impurities, especially free gadolinium and degradation products, is required. Specifications for these impurities are set based on toxicological data and regulatory guidance (e.g., ICH guidelines).
• Stability Studies: Comprehensive stability studies demonstrating the API's shelf life under various storage conditions are essential.
• Supply Chain Transparency: Regulatory bodies increasingly demand transparency throughout the API supply chain, including the sourcing of raw materials and the identity of all manufacturing sites.

What is the Current Production Capacity and Availability?

Exact production capacities for gadopiclenol API are proprietary. However, the following can be inferred:

• Bracco Imaging: As the originator, Bracco likely maintains significant internal capacity to meet initial market demand. Their established manufacturing sites are designed for high-volume production of contrast agents.
• Potential CMO Involvement: If demand outstrips Bracco's internal capacity, or as part of their supply chain diversification strategy, they may engage CMOs. The capacity of these CMOs would be critical for broader market penetration.
• Market Launch Status: Given the recent FDA approval (2023), API production is ramping up. Availability is currently tied to Bracco's supply chain and their commercialization strategy for VUEWAY. The number of API suppliers is expected to grow as patents expire and generic manufacturers enter the market.

What are the Potential Supply Chain Risks and Mitigation Strategies?

Supply chain risks for gadopiclenol API are multifaceted, similar to other specialized pharmaceutical ingredients:

• Single-Source Dependency: Reliance on a single API manufacturer (Bracco Imaging) presents a significant risk. Any disruption at their facility could halt supply.
  • Mitigation: Bracco may be developing secondary sources or utilizing CMOs with redundant capacity. Pharmaceutical companies typically qualify multiple suppliers for critical APIs, though this may be limited for a newly approved drug.
• Geopolitical Instability and Raw Material Sourcing: Geopolitical events can impact the availability and cost of raw materials, including gadolinium.
  • Mitigation: Diversifying raw material suppliers and maintaining strategic inventory levels can mitigate this risk. For gadolinium, this may involve sourcing from different global regions.
• Regulatory Hurdles for New Suppliers: Qualifying a new API supplier is a lengthy and complex process involving rigorous audits and DMF filings. This delays the introduction of alternative sources.
  • Mitigation: Proactive engagement with regulatory bodies and investing in robust quality systems by potential new manufacturers can streamline this process.
• Quality Control Failures: Any lapse in quality control can lead to batch rejection, supply interruptions, and significant reputational damage.
  • Mitigation: Implementing stringent in-process controls, comprehensive analytical testing, and robust quality management systems by all parties in the supply chain are essential.
• Intellectual Property (IP) Landscape: The patent landscape for gadopiclenol and its manufacturing processes will influence the entry of generic competitors and the expansion of API sources.
  • Mitigation: Thorough IP analysis is required to understand market entry timelines for potential generic manufacturers.

Key Takeaways

• Bracco Imaging S.p.A. is the primary identified bulk API manufacturer for gadopiclenol, leveraging its originator status and in-house capabilities.
• The synthesis of gadopiclenol API is complex, demanding specialized expertise in chelation chemistry and strict adherence to cGMP regulations.
• Regulatory compliance, particularly regarding impurity control and DMF filings, is a critical barrier to entry for new API manufacturers.
• Supply chain risks include potential single-source dependency on Bracco and the geopolitical volatility of rare-earth element sourcing.
• The introduction of alternative API suppliers is expected to be gradual, influenced by patent expirations and the significant regulatory and technical hurdles involved.

Frequently Asked Questions

1. Are there any publicly listed CMOs currently manufacturing gadopiclenol API? Publicly available information does not identify specific CMOs contracted for gadopiclenol API production. Such arrangements are typically confidential.
2. What is the typical lead time for qualifying a new gadopiclenol API supplier? Qualifying a new API supplier for a complex molecule like gadopiclenol typically takes 18-24 months, involving facility audits, process validation, and regulatory submissions.
3. How does the cost of gadopiclenol API compare to other macrocyclic gadolinium-based contrast agents? Specific API pricing is not publicly disclosed. However, the complex synthesis and specialized raw materials suggest a premium cost structure for gadopiclenol API, comparable to other advanced macrocyclic agents.
4. What is the estimated global demand for gadopiclenol API post-launch? Estimates vary based on market penetration and dosing strategies. Initial demand is projected to grow, with potential for several metric tons annually as market adoption increases.
5. What are the primary quality control challenges in gadopiclenol API manufacturing? The primary challenges include the precise control of chelation to minimize free gadolinium ions and the rigorous quantification of all process-related impurities to meet stringent safety standards.

Citations

[1] Grand View Research. (2023, October). MRI Contrast Agents Market Size, Share & Trends Analysis Report By Type (Gadolinium, Iodine, Others), By Application (Neurology, Cardiology, Oncology, Others), By Region, And Segment Forecasts, 2024 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/mri-contrast-agents-market